Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
      • Neuroimmunology: To Sense and Protect
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Arthropod- and Host-Specific Borrelia burgdorferi bbk32 Expression and the Inhibition of Spirochete Transmission

Erol Fikrig, Wen Feng, Stephen W. Barthold, Sam R. Telford III and Richard A. Flavell
J Immunol May 15, 2000, 164 (10) 5344-5351; DOI: https://doi.org/10.4049/jimmunol.164.10.5344
Erol Fikrig
*Section of Rheumatology, Department of Internal Medicine,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen Feng
†Section of Immunobiology, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen W. Barthold
§Center for Comparative Medicine, Schools of Medicine and Veterinary Medicine, University of California, Davis, CA 95616; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sam R. Telford III
¶Department of Tropical Public Health, Harvard University School of Public Health, Boston, MA 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard A. Flavell
†Section of Immunobiology, and
‡Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06520;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Antisera to BBK32 (a Borrelia burgdorferi fibronectin-binding protein) and BBK50, two Ags synthesized during infection, protect mice from experimental syringe-borne Lyme borreliosis. Therefore, B. burgdorferi bbk32 and bbk50 expression within Ixodes scapularis ticks and the murine host, and the effect of BBK32 and BBK50 antisera on spirochetes throughout the vector-host life cycle were investigated. bbk32 and bbk50 mRNA and protein were first detected within engorged ticks, demonstrating regulated expression within the vector. Then bbk32 expression increased in mice at the cutaneous site of inoculation. During disseminated murine infection, bbk32 and bbk50 were expressed in several murine tissues, and mRNA levels were greatest in the heart and spleen at 30 days. BBK32 antisera protected mice from tick-borne B. burgdorferi infection and spirochete numbers were reduced by 90% within nymphs that engorged on immunized mice. Moreover, 75% of these ticks did not retain spirochetes upon molting, and subsequent B. burgdorferi transmission by adult ticks was impaired. Larval acquisition of B. burgdorferi by I. scapularis was also inhibited by BBK32 antisera. These data demonstrate that bbk32 and bbk50 are expressed during tick engorgement and that BBK32 antisera can interfere with spirochete transmission at various stages of the vector-host life cycle. These studies provide insight into mechanisms of immunity to Lyme borreliosis and other vector-borne diseases.

Borrelia burgdorferi, the causative agent of Lyme disease, expresses different genes during its life cycle (1, 2, 3). In the gut of Ixodes scapularis ticks, spirochetes abundantly synthesize outer surface protein (Osp)3 A (4, 5, 6). When ticks engorge, B. burgdorferi begin to express ospC and down-regulate ospA (4, 5, 7). Several genes are then subsequently expressed during mammalian infection, including ospE/F paralogues (erps), bbk32 and bbk50, among others (8, 9, 10, 11, 12, 13, 14, 15, 16, 17). bbk32 encodes a 47-kDa fibronectin-binding protein: this gene was initially named p35 based on partial sequence data that were available before the publication of the B. burgdorferi genome, and subsequently designated as p47 or bbk32 (11, 13, 18). Similarly, the p37 gene corresponds to the bbk50 genome sequence, and unrelated 37-kDa proteins have been described (11, 18, 19). To avoid confusion, the bbk32 and bbk50 designations for the genes previously referred to as p35 and p37 will be used throughout this manuscript (18).

B. burgdorferi N40 preferentially synthesize BBK32 and BBK50 during murine and human Lyme disease. These proteins were first simultaneously identified by differentially probing a B. burgdorferi N40 expression library with sera from B. burgdorferi-infected mice and sera from mice hyperimmunized with killed spirochetes (11, 16). RT-PCR and immunofluorescence studies then directly showed that bbk32 and bbk50 were expressed in vivo but not in vitro (11, 20). BBK32 and BBK50 Abs were also found in the sera of B. burgdorferi-infected mice and individuals with Lyme disease, further indicating that these Ags were synthesized during infection of the vertebrate host (11, 21). Studies by Probert and Johnson (13) then showed that BBK32 is a fibronectin-binding protein and plays an important role in the attachment of spirochetes to the extracellular matrix. These studies also confirmed that BBK32 was not synthesized by B. burgdorferi N40 during in vitro cultivation (13). It was also demonstrated, however, that five of six Borrelia species and four of eight B. burgdorferi sensu lato isolates synthesized BBK32 or other fibronectin-binding proteins when cultured in BSK II medium (13, 22).

Humoral responses to BBK32 and BBK50 can influence the course of Lyme borreliosis. Murine arthritis and carditis develops at 2–4 wk and regresses during the subsequent 1–2 mo. The resolution of disease correlated with the genesis of high-titer BBK32 and BBK50 Abs (11). The ability of BBK32 and BBK50 Abs to afford immunity was therefore directly tested. Active immunization with BBK32 and BBK50, or passive immunization with BBK32 and BBK50 antisera, partially protected mice from challenge with a syringe inocula of spirochetes (11). Partial or complete immunity following vaccination has been observed with several other B. burgdorferi proteins, most notably OspA, OspB, OspC, OspF, and decorin-binding protein (Dbp) A (23, 24, 25, 26, 27, 28, 29). OspA has been the most extensively studied immunogen, has successfully completed phase III clinical trials, and has been approved by the Federal Drug Administration for use as a vaccine against Lyme disease (30, 31).

The administration of BBK32 and BBK50 Abs to mice that had been infected with spirochetes for 24 h also eradicated B. burgdorferi infection (11). Postinfection clearance of B. burgdorferi has not been observed with OspA Abs and has only been described in experimental syringe-challenge studies with Abs to OspC and DbpA (29, 32, 33, 34). To extend these observations to human infection, the Ag-specific humoral responses in a cohort of patients with untreated Lyme disease were correlated with progression from early- to late-stage disease (21). High levels of BBK32 Abs were associated with early-stage disease that resolved, whereas the lack of significant BBK32 Abs resulted in an increased likelihood of the development of late-stage Lyme arthritis. These studies suggest that BBK32 and BBK50 Abs, and in particular BBK32 Abs, can affect the course of Lyme disease in mice or humans.

An investigation of bbk32 and bbk50 expression throughout the spirochete life cycle should provide a more realistic understanding of the importance of these proteins. Research on the selective expression of bbk32 and bbk50 in vivo has relied upon comparing spirochetes cultured in BSK II medium with B. burgdorferi in mice following experimental challenge with inocula of in vitro-cultivated organisms. Obviously, spirochetes are not normally exposed to BSK II medium, but rather persist in a tick-mouse-tick cycle (1). More specifically, spirochetes reside in particular tissues in the vector or host at precise intervals during infection. B. burgdorferi are located in the gut of flat I. scapularis and migrate to the salivary glands of feeding ticks before moving to a reservoir host. Spirochetes are then deposited into the host skin. After several days, B. burgdorferi disseminate via the bloodstream to distant tissues. Spirochetes must then return from the host to the ticks that feed on B. burgdorferi-infected mice because the efficiency of transovarial transmission is low (35). Temporal and tissue-specific B. burgdorferi gene expression should consider these diverse niches.

Materials and Methods

Spirochetes

A clonal isolate of B. burgdorferi N40 that is infectious and pathogenic in mice was used throughout (36). Spirochetes were cultivated in BSK II medium at 33°C (37).

Animals

Three-week-old female C3H/HeNCr (C3H) and C.B-17-scid mice were obtained from the Frederick Cancer Research Center (Frederick, MD) and housed in filter-frame cages. Mice were given food and water ad libitum and euthanized with CO2.

Two hundred- to 500-g female Hartley guinea pigs were housed in individual hanging cages at Yale University animal facilities.

Ticks

Mated adult female I. scapularis were collected in the field. The egg mass was then laid in the laboratory. Hatched larvae were fed on uninfected C3H mice to produce pathogen-free nymphs. Alternatively, to generate B. burgdorferi-infected nymphal ticks, larvae were allowed to engorge to repletion upon B. burgdorferi N40-infected mice and then molt to the nymphal stage. B. burgdorferi infection rates within the nymphs were >90%. All tick rearing was performed in an incubator at 26°C with 85% relative humidity and a 12-h:12-h light:dark photo period regimen.

Infection and immunization

For infection, 4- to 6-wk-old C3H mice were intradermally challenged with 104 B. burgdorferi N40 and sacrificed at 14, 30, and 60 days. In an experiment, groups of 10–20 mice were inoculated with B. burgdorferi and 4–5 mice were sacrificed at each time point. All studies were repeated, and in each experiment, tissue samples from each mouse were collected and stored individually.

For the postinfection clearance studies, mice were first infected with 104 spirochetes by intradermal syringe inoculation and administered 200 μl of rabbit BBK32 and BBK50 antisera on days 1, 2, 4, or 8 (11). Control mice were administered glutathione transferase (GT) antisera in an identical manner (11). The BBK32 and BBK50 antisera had been previously produced (11). BBK32 antisera were prepared by immunizing animals with the p35 portion of the BBK32 protein and have been shown to be immunogenic in the murine model (11). The full-length BBK32 protein from B. burgdorferi N40 has also been produced in our laboratory, but is not highly antigenic in its current form (data not shown) and was therefore not used for these studies. Mice were killed at 14 days. At necropsy, blood, spleen, urinary bladder, and skin specimens were collected aseptically, cultured in BSK II medium, and examined by dark-field microscopy for spirochetes. The tibiotarsal joints and the hearts were Formalin-fixed, paraffin-embedded, sectioned, and examined microscopically for inflammation (36). Arthritis was graded by blinded analysis on a scale from 0, no inflammation, to 3, severe disease (36).

For the larval acquisition studies, groups of four to five C.B.17-scid mice were infected with 104 B. burgdorferi by intradermal challenge. At 20 days, mice were passively immunized with 200 μl of BBK32 and BBK50 antisera or a control GT antiserum. Twenty-four hours after passive immunization, mice were anesthetized with ketamine/xylazine and 50 larvae were placed on each mouse. The larvae fed to repletion and were examined for spirochetes. Individual larvae were tested by immunofluorescence (see below), using B. burgdorferi-antisera, for the presence of spirochetes.

For the tick-borne transmission studies, groups of four to five mice were first administered 200 μl of BBK32 and BBK50 antisera. Twenty-four hours later, 4 or 20 I. scapularis nymphs, infected with B. burgdorferi N40, were allowed to feed to repletion on each of the mice. Engorged ticks usually fell from the animals within 4 days and were collected in water baths below the cages. Two weeks later, all mice were sacrificed and examined for infection and disease, as previously stated.

In the guinea pig infection studies, a 5- to 10-cm section of the animals’ posterior mid thorax was shaved and then three to four adult ticks were applied per guinea pig and allowed to attach. The adult ticks were obtained from groups of nymphal ticks that had fed upon mice immunized with BBK32, BBK50, or GT antisera and then allowed to undergo the molting process. Guinea pigs were sacrificed 2 wk after tick challenge. Sera were collected and tested for Abs to B. burgdorferi by immunoblot (38).

PCR

PCR amplification of B. burgdorferi DNA was performed for 30 cycles with denaturing, annealing, and extension temperatures of 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min. 5′ and 3′ primers were: 5′-CAATCAGGTAACGGC-3′ and 5′-TCTATTTTGGAAAGC-3′ for flaB, 5′-GC GGTGAAAGTGGTGAATTGG-3′ and 5′-CTTTAGCAAAGTTGTCAAGGCGTG-3′ for bbk32, and 5′-GACAACAACAGAAGTGGTCGCAC-3′ and 5′-TAGCATCGGAA TGAGCTGTACC-3′ for bbk50. flaB, which has one copy on the B. burgdorferi chromosome, was used to quantify the organism load (18).

For RT-PCR, total RNA was isolated from the spleens, skin, tibiotarsal joints, bladders, and hearts of B. burgdorferi-infected mice by acid guanidinium thiocyanate phenol-chloroform extraction (16). RNA was treated with RNase-free DNase (Promega, Madison WI) for 3 h at 37°C. A total of 2 μg of RNA was then reverse transcribed using Moloney murine leukemia virus reverse transcriptase (Stratagene, La Jolla, CA). PCR was then conducted for 30 cycles.

For quantitative PCR, a competition assay was performed based on established techniques (12, 39). Competitor constructs were created in which a 540-bp fragment of unrelated DNA was flanked by the flaB, bbk32, or bbk50 primers. The unrelated DNA was a fragment of the gene encoding the 44-kDa Ag of the agent of human granulocytic ehrlichiosis, amplified using the Ehrlichia primers 5′-TTTGCAGGACGAAGAAGAATGG-3′ and 5′-CCAACGCAAGCATAAGGAACAAC-3′, which have previously been used in constructs for competitive PCR (40). Varying concentrations of competitor were added to the RT-PCR reactions, and the concentration at which the amplified competitor product and the gene of interest were similar in intensity was used to calculate the quantity of mRNA or DNA.

Immunofluorescence of B. burgdorferi within ticks

Groups of B. burgdorferi N40-infected ticks, including unfed ticks and ticks that fed to repletion on mice, were checked for spirochetes, and the presence of specific B. burgdorferi Ags, within the vector by indirect immunofluorescence (IFA). Each tick was dissected to separate the internal organs from the cuticle and lightly homogenized in 100 μl of PBS. Then triplicate 10-μl aliquots were spotted on silylated glass slides. The slides were air dried and fixed with 4% paraformaldehyde. The specimens were incubated in rabbit BBK32, BBK50, OspC, or OspA antisera (1:100 dilution) for 1 h, washed, followed by incubation in anti-rabbit IgG coupled with FITC at a 1:500 dilution for another hour, and viewed under a Zeiss Axioskop fluorescence microscope (Oberkochen, Germany) (11, 27, 41). B. burgdorferi antisera or FlaB antisera, which recognizes B. burgdorferi within both unfed and engorged ticks, was used as positive controls (4, 40). GT antisera was used as the negative control. Ten high-power fields (×400) were examined, and the total number of spirochetes was calculated.

Results

B. burgdorferi bbk32 and bbk50 expression during murine infection

bbk32 and bbk50 have been shown to be induced during murine infection and in several patients with erythema migrans or Lyme arthritis (11, 20). We have now quantitatively examined the temporal and tissue-specific expression of B. burgdorferi bbk32 and bbk50 during experimental murine Lyme borreliosis. Following intradermal challenge, spirochetes are deposited in the skin and then begin disseminating (4–10 days) to the joints, heart, spleen, and bladder (36, 42). Arthritis and carditis then become prominent (2–4 wk) and regress over 1–2 mo (36, 42). At later intervals, mice remain infected but disease is no longer apparent (36, 42). bbk32 and bbk50 mRNA levels were therefore first measured at the cutaneous site of inoculation from days 1 to 14 (Fig. 1⇓) and then at different disseminated sites on days 14, 30, and 60, intervals that reflect the various stages of disease (Table I⇓). flaB mRNA, which is constitutively expressed, was used for comparison (12). Representative examples of the flaB, bbk32, and bbk50 quantitative RT-PCR are shown in Fig. 2⇓.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

bbk32, bbk50, and flab mRNA levels at the initial cutaneous site following challenge with 104 B. burgdorferi via intradermal syringe inoculation. mRNA levels were measured by quantitative RT-PCR and expressed as femtograms per skin specimen. Each skin sample weighed 20 mg.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Representative competitive RT-PCR assays to quantify flaB (A), bbk50 (B), and bbk32 (C) mRNA levels during murine infection with B. burgdorferi. In all panels, the upper band represents the competitor construct, which was added in increasing concentrations from lanes 1 to 6. Amount of competitor: lane 1, 3.2 × 10−10 μg; lane 2, 1.1 × 10−9 μg; lane 3, 8 × 10−9 μg; lane 4, 4 × 10−8 μg; lane 5, 2 × 10−7 μg; and lane 6, 2 × 10−6 μg. The lower band represents the amplified B. burgdorferi product.

View this table:
  • View inline
  • View popup
Table I.

B. burgdorferi bbk32, bbk50, and flaBmRNA levels in specific tissues during experimental murine Lyme borreliosisa

At the local skin site, following the intradermal inoculation of 104 spirochetes, flaB mRNA was detected (3.8 ± 1.3 femtograms/tissue specimen) on day 1 (Fig. 1⇑). At this time point, quantitative DNA-PCR revealed that 2 × 104 ± 0.5 × 104 spirochetes were present at the site of inoculation, representing the original inocula and perhaps some initial spirochete growth. By day 6, flaB mRNA levels increased 10-fold (37 ± 10 femtograms/tissue specimen) from the initial values before declining on day 14. Quantitative DNA-PCR demonstrated that the spirochete number increased up to 3 × 105 ± 0.6 × 105 on day 6 before declining, reflecting the changes in flaB mRNA detection, and further demonstrating that flaB mRNA levels can be used to follow spirochete burden in infected mice (12). bbk32 ands bbk50 mRNA levels were not significant on day 1, consistent with previous studies that B. burgdorferi N40 does not immediately express these genes following intradermal syringe challenge. Low levels of bbk50 were detected at the local site of inoculation on days 4–14 and reached levels of up to 6.0 ± 2 femtograms/tissue specimen on day 5. As the number of total spirochetes declines at the local site of inoculation on day 14, more bbk50 mRNA is expressed per spirochete at this later interval than at earlier time points. bbk32 mRNA levels greatly increased from days 3 to 7 and then declined. The change in bbk32 expression is consistent with the study of Probert and Johnson (13) demonstrating the BBK32 is a fibronectin-binding protein and may therefore required during the initial stage of infection.

Gene expression in the skin, joints, heart, spleen, and bladder was then assessed during disseminated murine infection (Table I⇑). Skin specimens were obtained from the murine mid-posterior thorax, away from the site of inoculation. flaB mRNA was detected in all of the tissues and at all intervals, confirming that spirochetes were present at these locations and that B. burgdorferi mRNA had been successfully isolated. flaB mRNA levels increased from days 14 to 30 and then decreased at 60 days, consistent with studies suggesting that the number of spirochetes decrease in mice as the host immune response to B. burgdorferi expands. At 14, 30, and 60 days, flaB mRNA levels were generally greater in the joints, heart, and spleen than in the skin and bladder, suggesting that the spirochete burden is higher in these tissues. bbk32 and bbk50 mRNA levels were lower than flaB mRNA levels at each location. At 14 days, bbk32 and bbk50 mRNA levels were generally similar in the tissues examined. At 30 days, bbk32 mRNA levels in the skin, heart, and spleen were greater than the bbk50 mRNA levels, particularly in the spleen. bbk32 and bbk50 mRNA levels in the joints and bladder at 30 days were not different. At 60 days, bbk32 and bbk50 mRNA levels declined as the number of spirochetes decreased in all tissues; however, spirochetes in the spleen continued to produce more bbk32 than bbk50 mRNA.

B. burgdorferi bbk32 and bbk50 expression in ticks

Previous research demonstrated that B. burgdorferi N40 expressed bbk32 and bbk50 during mammalian infection but not when cultured in vitro (11). B. burgdorferi are, however, maintained in a natural vector-host-vector cycle and not usually exposed to laboratory medium. bbk32 and bbk50 expression in ticks was therefore investigated to further understand when these genes are normally expressed. Individual spirochetes within ticks are readily discernible by IFA, unlike B. burgdorferi within murine tissues. Therefore IFA rather than RT-PCR was primarily used to examine spirochetes within the vector. BBK32 and BBK50 Ag on spirochetes within flat and engorged I. scapularis were examined by immunofluorescence using BBK32 or BBK50 antisera. BBK32 and BBK50 were not evident on spirochetes within unfed ticks but were apparent on B. burgdorferi in engorged ticks (Fig. 3⇓). The number of BBK32- and BBK50-producing spirochetes was determined by probing B. burgdorferi within flat and fed ticks with selected antisera. Fields containing ∼1000 spirochetes were first examined by dark-field microscopy. As the number of B. burgdorferi within ticks increases exponentially during engorgement, a larger number of fields from flat tick extracts were required to identify 1000 organisms. Following engorgement, 57 ± 3% of B. burgdorferi synthesized BBK32 and 78 ± 4% produced BBK50 (Fig. 4⇓). As expected, B. burgdorferi- or FlaB antisera (controls) readily identified spirochetes in flat and engorged ticks. OspA-producing spirochetes were only abundant in the flat ticks, and OspC-synthesizing organisms increased in number during feeding, consistent with previous reports (4, 5, 7). RT-PCR substantiated the IFA results (Fig. 5⇓). bbk32 and bbk50 mRNA were detected in engorged, but not flat ticks, whereas flaB mRNA (control) was evident in both groups of ticks. These studies demonstrated that bbk32 and bbk50 are expressed on B. burgdorferi within feeding I. scapularis ticks.

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

Immunofluorescence of spirochetes within engorged (A, C, E, and G) or flat (B, D, F, and H) ticks probed with specific antisera. A and B, B. burgdorferi-antisera. C and D, BBK32 antisera. E and F, BBK50 antisera. G and H, GT antisera (control).

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

Number of spirochetes within flat or engorged ticks that can be detected with selected antisera. Antisera used: B. burgdorferi, BBK32, BBK50, FlaB, OspA, OspC, and GT (control). The means ± SD of three experiments are shown.

FIGURE 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5.

RT-PCR to detect B. burgdorferi bbk32, bbk50, or flaB mRNA within flat (A) or engorged (B) ticks. Lane 1, Molecular mass marker; lane 2, flaB; lane 3, bbk32; and lane 4, bbk50. +, with reverse transcriptase; −, without reverse transcriptase.

Immunization with BBK32 antisera is protective against tick-borne B. burgdorferi infection: BBK32 and BBK50 antisera do not, however, clear spirochetes from persistently infected animals

BBK32 and BBK50 antisera have previously been shown to protect mice from experimental challenge with an intradermal inocula of spirochetes and also to clear B. burgdorferi from mice infected with spirochetes for 24 h (11). We have now performed studies to examine whether the postinfection immunity phenomenon extends to later intervals after infection (Table II⇓). Results were similar when 102 rather than 104B. burgdorferi were used as the challenge inocula (data not shown). Partial eradication was observed when BBK32 and BBK50 antisera were administered up to 2 days after infection. At 4 and 8 days after infection, when spirochetes had begun to disseminate from the skin to distant organs, B. burgdorferi clearance was no longer evident. In addition, passive immunization with BBK32 and BBK50 antisera at these intervals did not influence the severity of disease in the B. burgdorferi-infected mice. Arthritis was graded on a scale from 0 to 3, with 1, 2 and 3 representing mild, moderate, and severe inflammation, respectively. Tibiotarsal joints from BBK32- and BBK50-immunized mice had mild to moderate arthritis (1.7 mean ± 0.6 SD, similar to control mice (1.5 mean ± 0.5 SD).

View this table:
  • View inline
  • View popup
Table II.

Passive immunization with BBK32 and BBK50 antisera against murine Lyme borreliosisa

Our results have now demonstrated that B. burgdorferi express bbk32 and bbk50 within ticks during engorgement before transmission to the host. We therefore also studied whether BBK32 and BBK50 Abs could protect mice against tick-borne infection (Table II⇑). Passive transfer of murine BBK32 antisera to naive mice partially prevented B. burgdorferi infection transmitted by tick bite. Murine BBK50 antisera did not provide immunity and the combination of murine BBK32 and BBK50 antisera did not afford greater protection than murine BBK32 antisera alone. Although the passive transfer of murine BBK32 antisera was partially protective against B. burgdorferi infection when 4 ticks engorged on mice, protection was not obtained when 20 ticks were placed on each animal.

Influence of BBK32 and BBK50 antisera on B. burgdorferi within ticks

Spirochetes synthesize BBK32 and BBK50 within ticks during engorgement and BBK32 antisera provides partial protection against tick-borne infection. Therefore, the effects of BBK32 and BBK50 antisera on spirochetes within engorging ticks were examined. The number of spirochetes within ticks that fed on mice administered BBK32 or BBK50 antisera were assessed by IFA (Table III⇓). Spirochetes were abundant in nymphal ticks that fed on mice given GT antisera (control). B. burgdorferi within ticks that engorged on mice administered BBK50 antisera also had substantial numbers of spirochetes. Ticks that fed on mice given BBK32 antisera had markedly fewer spirochetes (90% less) and the combination of BBK32 and BBK50 antisera did not result in a greater reduction in spirochete number.

View this table:
  • View inline
  • View popup
Table III.

Spirochete within ticks that fed on mice passively immunized with BBK32 or BBK50 antiseraa

The effect of BBK32 antisera on the survival of spirochetes following the molt was then examined. Nymphs that had engorged on immunized mice were allowed to molt to the adult stage over several months. Adult ticks were then examined for spirochetes using IFA. B. burgdorferi were readily detected within adult ticks that had been exposed to GT or BBK50 antisera during nymphal engorgement. All 12 GT-exposed ticks had spirochetes. Seven of 11 ticks exposed to BBK50 antisera had spirochetes. Only 2 of 11 ticks exposed to both BBK32 and BBK50 antisera and 3 of 12 ticks exposed to BBK32 antisera had B. burgdorferi. In addition, adult ticks that had been previously exposed to BBK32 or BBK32 and BBK50 antisera had markedly fewer spirochetes than controls (Table III⇑). The number of spirochetes in adult control ticks was less than that in engorged control nymphs because B. burgdorferi increase in number during tick feeding.

We then performed studies to determine whether this reduction in B. burgdorferi due to BBK32 antisera could prevent spirochete transmission from ticks to a mammalian host. Guinea pigs were used for these experiments because adult ticks do not engorge on mice and guinea pigs can be infected with B. burgdorferi (38, 43). Four or five adult ticks that had been exposed to GT, BBK32, or BBK50 antisera during nymphal engorgement were allowed to feed to repletion on guinea pigs. The guinea pigs were then assessed for exposure to B. burgdorferi infection by immunoblot (38). Guinea pigs fed upon by GT (three of four animals) or BBK50 (three of three animals) antisera-exposed ticks, but not ticks exposed to BBK32 (zero of four animals) or BBK32 and BBK50 (zero of three animals) antisera had evidence of B. burgdorferi infection. These data demonstrate that BBK32 antisera inhibited spirochete transmission by adult ticks.

BBK32 and BBK50 antisera inhibits larval acquisition

BBK32 Abs play an important role in B. burgdorferi survival within ticks. Therefore, the effects of BBK32 and BBK50 antisera on the larval acquisition of spirochetes were examined because these Ags are synthesized within engorging ticks and during mammalian infection. SCID mice were infected with B. burgdorferi and at 14 days the animals were administered BBK32 and BBK50 antisera. Larvae were allowed to engorge on the mice and spirochete transmission from the host to larvae was examined by IFA (Fig. 6⇓). Larvae that engorged on control animals had large numbers of spirochetes. In contrast, ticks that fed on BBK32- and BBK50-immunized mice had reduced numbers of B. burgdorferi.

FIGURE 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 6.

Number of spirochetes within larvae that engorged on B. burgdorferi-infected SCID mice that had been passively immunized with BBK32 and BBK50 antisera. Groups of five mice were infected with B. burgdorferi for 2 wk and then administered antisera. Four larval ticks were then allowed to feed to repletion on the mice, collected, and then dissected and examined for spirochetes by immunofluorescence.

Discussion

The expression of bbk32 and bbk50 during the spirochete life cycle in the I. scapularis tick and the murine host was extensively examined. Our studies demonstrate that bbk32 and bbk50 are expressed by B. burgdorferi N40 within ticks during the process of engorgement. Since these genes are located on different plasmids, it is most likely that expression is temporally associated, but not genetically linked. Over the past 5 years, it has been shown that several of the genes that are expressed and are antigenic during infection appear to first be induced within the feeding tick. For example, OspC, an Ag that is readily recognized by Abs during the early stage of infection, is first expressed by spirochetes during tick engorgement (7). In contrast, other in vivo-expressed genes, such as erpT and p21, are predominantly down-regulated within the vector and then only expressed in the mammalian host (10, 12).

We then performed a detailed analysis of the expression of bbk32 and bbk50 during murine Lyme borreliosis. In contrast with erpT, an in vivo-expressed gene which appears to be most prominently expressed in extracutaneous tissues, bbk32 and bbk50 expression were apparent in diverse tissues, including the skin, joints, heart, spleen, and bladder of infected mice (12). Expression was most abundant on day 30 and then declined. At this later interval (60 days), mice have developed high titer BBK32 and BBK50 Abs, and the lower levels of expression may represent either the destruction of spirochetes expressing bbk32 or bbk50 or the down-regulation of gene expression. Our early time points studies also demonstrate that bbk32 and bbk50 are expressed at low levels early after intradermal inoculation and that bbk32 expression then rapidly increases at a greater rate than bbk50 at the local site of inoculation.

BBK32 antisera influenced spirochete survival at various intervals in the B. burgdorferi life cycle, most prominently in the tick. We demonstrated that the “postinfection clearance” of BBK32 and BBK50 is not apparent after 2 days. One hypothesis to account for this short-lived effect is that the accessibility of these proteins to Ab during the course of infection may influence protective immunity (44). Various Abs have borreliacidal effects at different intervals of infection. OspA Abs are only protective when administered before spirochete challenge, presumably because of the substantial down-regulation of ospA expression in vivo. In contrast, BBK32 Abs have an early clearance effect similar to what has been seen with DbpA Abs (29). Since both BBK32 and DbpA mediate spirochete attachment to the extracellular matrix, these Abs may influence B. burgdorferi at this location, perhaps before spirochetes have been able to coat themselves with fibronectin or decorin. In contrast, Abs to OspC, when repeatedly administered in high doses, have the capacity to clear spirochetes after several weeks of infection, a phenomenon that has not been demonstrated with other antisera (33, 34). Therefore, Abs to different in vivo-expressed proteins, when used together, and at different intervals may have synergistic effects on preventing spirochete survival and persistence.

BBK32 antisera has a significant impact on the survival of spirochetes within ticks and in the ability of ticks to maintain spirochetes throughout the molt. Spirochete numbers are reduced, but not eradicated, within ticks that engorged on BBK32-immunized mice and adult ticks could then not readily transmit B. burgdorferi to guinea pigs. These data show that the Abs interfere with the capacity of ticks to retain organisms and transmit infection. This effect is also evident during larval acquisition, for BBK32 and BBK50 antisera interfered with the ability of larval ticks to acquire spirochetes when feeding on immunized SCID mice. The ability of these antisera to affect spirochetes in the vector may account for enhanced protection against tick-borne challenge rather than needle inoculation.

BBK32 and BBK50 are two B. burgdorferi genes that are expressed during tick feeding and then also during systemic murine infection. Abs to these proteins, in particular BBK32, can partially protect mice from tick-borne infection with B. burgdorferi and may therefore be used as alternative vaccines that destroy B. burgdorferi at different time points. The diversity, and expression, of BBK32 by different B. burgdorferi isolates will help determine whether BBK32 will have broader utility as an immunogen. BBK32 antisera also had the capacity to affect spirochete survival within ticks, especially during the molting process. Therefore, another strategy to control B. burgdorferi would be to selectively immunize the natural reservoir, i.e., Peromyscus leucopus, with BBK32, thereby reducing the larval acquisition of spirochetes, and the ability of engorged nymphs and adults to harbor the pathogen. A detailed understanding of the temporal expression of B. burgdorferi genes and the specific location in which Abs can exert pressure on the spirochete may lead to new rational approaches to multivalent vaccines that can effect the spirochete during different stages of the B. burgdorferi life cycle.

Footnotes

  • ↵1 This work was supported by grants from the National Institutes of Health (AI-45253, AI-37993, AI-26815, and AI-49387), the Arthritis Foundation, and the American Heart Association. E.F. is the recipient of a Burroughs Wellcome Clinical Scientist Award in Translational Research. R.A.F. is an Investigator of the Howard Hughes Medical Institute.

  • ↵2 Address correspondence and reprint requests to Dr. Richard A. Flavell, Section of Immunobiology, Yale University School of Medicine, 310 Cedar Street, FMB 412, P.O. Box 208011, New Haven, CT 06520-8011. E-mail address: fran.manzo{at}yale.edu

  • ↵3 Abbreviations used in this paper: Osp, outer surface protein; Dbp, decorin-binding protein; GT, glutathione transferase; IFA, indirect immunofluorescence.

  • Received October 8, 1999.
  • Accepted March 2, 2000.
  • Copyright © 2000 by The American Association of Immunologists

References

  1. ↵
    Schwan, T. G.. 1996. Ticks and Borrelia: model systems for investigating pathogen-arthropod interactions. Infect. Agents Dis. 5: 167
    OpenUrlPubMed
  2. ↵
    Nadelman, R. B., G. P. Wormser. 1998. Lyme borreliosis. Lancet 352: 557
    OpenUrlCrossRefPubMed
  3. ↵
    de Silva, A. M., E. Fikrig. 1997. Arthropod- and host-specific gene expression by Borrelia burgdorferi. J. Clin. Invest. 99: 377
    OpenUrlCrossRefPubMed
  4. ↵
    de Silva, A. M., S. R. Telford, L. R. Brunet, S. W. Barthold, E. Fikrig. 1996. Borrelia burgdorferi OspA is an arthropod-specific transmission- blocking Lyme disease vaccine. J. Exp. Med. 183: 271
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Coleman, J. L., J. A. Gebbia, J. Piesman, J. L. Degen, T. H. Bugge, J. L. Benach. 1997. Plasminogen is required for efficient dissemination of Borrelia burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell 89: 1111
    OpenUrlCrossRefPubMed
  6. ↵
    Fingerle, V., U. Hauser, G. Liegl, B. Petko, V. Preac-Mursic, B. Wilske. 1995. Expression of outer surface proteins A and C of Borrelia burgdorferi in Ixodes ricinus. J. Clin. Microbiol. 33: 1867
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Schwan, T. G., J. Piesman, W. T. Golde, M. C. Dolan, P. A. Rosa. 1995. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc. Natl. Acad. Sci. USA 92: 2909
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Cassatt, D. R., N. K. Patel, N. D. Ulbrandt, M. S. Hanson. 1998. DbpA, but not OspA, is expressed by Borrelia burgdorferi during spirochetemia and is a target for protective antibodies. Infect. Immun. 66: 5379
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Champion, C. I., D. R. Blanco, J. T. Skare, D. A. Haake, M. Giladi, D. Foley, J. N. Miller, M. A. Lovett. 1994. A 9.0-kilobase-pair circular plasmid of Borrelia burgdorferi encodes an exported protein: evidence for expression only during infection. Infect. Immun. 62: 2653
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Das, S., S. W. Barthold, S. S. Giles, R. R. Montgomery, S. R. Telford, III, E. Fikrig. 1997. Temporal pattern of Borrelia burgdorferi p21 expression in ticks and the mammalian host. J. Clin. Invest. 99: 987
    OpenUrlCrossRefPubMed
  11. ↵
    Fikrig, E., S. W. Barthold, W. Sun, W. Feng, S. R. Telford III, and R. A. Flavell. 1997. Borrelia burgdorferi P35 and P37 proteins, expressed in vivo, elicit protective immunity. [Published erratum appears in 1998, Immunity 9:755.] Immunity 6:531.
  12. ↵
    Fikrig, E., M. Chen, S. W. Barthold, J. Anguita, W. Feng, S. R. Telford, R. A. Flavell. 1999. Borrelia burgdorferi erpT expression in the arthropod vector and murine host. Mol. Microbiol. 31: 281
    OpenUrlCrossRefPubMed
  13. ↵
    Probert, W. S., B. J. Johnson. 1998. Identification of a 47 kDa fibronectin-binding protein expressed by Borrelia burgdorferi isolate B31. Mol. Microbiol. 30: 1003
    OpenUrlCrossRefPubMed
  14. ↵
    Stevenson, B., T. G. Schwan, P. A. Rosa. 1995. Temperature-related differential expression of antigens in the Lyme disease spirochete, Borrelia burgdorferi. Infect. Immun. 63: 4535
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Stevenson, B., J. L. Bono, T. G. Schwan, P. Rosa. 1998. Borrelia burgdorferi erp proteins are immunogenic in mammals infected by tick bite, and their synthesis is inducible in cultured bacteria. Infect. Immun. 66: 2648
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Suk, K., S. Das, W. Sun, B. Jwang, S. W. Barthold, R. A. Flavell, E. Fikrig. 1995. Borrelia burgdorferi genes selectively expressed in the infected host. Proc. Natl. Acad. Sci. USA 92: 4269
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Zhang, J. R., J. M. Hardham, A. G. Barbour, S. J. Norris. 1997. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 89: 275
    OpenUrlCrossRefPubMed
  18. ↵
    Fraser, C. M., S. Casjens, W. M. Huang, G. G. Sutton, R. Clayton, R. Lathigra, O. White, K. A. Ketchum, R. Dodson, E. K. Hickey, et al 1997. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 390: 580
    OpenUrlCrossRefPubMed
  19. ↵
    Gilmore, R. D., Jr, R. L. Murphree, A. M. James, S. A. Sullivan, B. J. Johnson. 1999. The Borrelia burgdorferi 37-kilodalton immunoblot band (P37) used in serodiagnosis of early Lyme disease is the flaA gene product. J. Clin. Microbiol. 37: 548
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Fikrig, E., W. Feng, J. Aversa, R. T. Schoen, R. A. Flavell. 1998. Differential expression of Borrelia burgdorferi genes during erythema migrans and Lyme arthritis. J. Infect. Dis. 178: 1198
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Akin, E., G. L. McHugh, R. A. Flavell, E. Fikrig, A. C. Steere. 1999. The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis. Infect. Immun. 67: 173
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Grab, D. J., C. Givens, R. Kennedy. 1998. Fibronectin-binding activity in Borrelia burgdorferi. Biochim. Biophys. Acta 1407: 135
    OpenUrlPubMed
  23. ↵
    Schaible, U. E., M. D. Kramer, K. Eichmann, M. Modolell, C. Museteanu, M. M. Simon. 1990. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc. Natl. Acad. Sci. USA 87: 3768
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Probert, W. S., R. B. LeFebvre. 1994. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect. Immun. 62: 1920
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Preac-Mursic, V., B. Wilske, E. Patsouris, S. Jauris, G. Will, E. Soutschek, S. Rainhardt, G. Lehnert, U. Klockmann, P. Mehraein. 1992. Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection. Infection 20: 342
    OpenUrlCrossRefPubMed
  26. ↵
    Nguyen, T. P., T. T. Lam, S. W. Barthold, S. R. Telford, R. A. Flavell, E. Fikrig. 1994. Partial destruction of Borrelia burgdorferi within ticks that engorged on OspE- or OspF-immunized mice. Infect. Immun. 62: 2079
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Fikrig, E., S. W. Barthold, N. Marcantonio, K. Deponte, F. S. Kantor, R. A. Flavell. 1992. Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect. Immun. 60: 657
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Fikrig, E., S. W. Barthold, F. S. Kantor, R. A. Flavell. 1990. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 250: 553
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Hanson, M. S., D. R. Cassatt, B. P. Guo, N. K. Patel, M. P. McCarthy, D. W. Dorward, M. Hook. 1998. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect. Immun. 66: 2143
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Sigal, L. H., J. M. Zahradnik, P. Lavin, S. J. Patella, G. Bryant, R. Haselby, E. Hilton, M. Kunkel, D. Adler-Klein, T. Doherty, et al. 1998. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease: recombinant outer-surface protein A Lyme disease vaccine study consortium. [Published erratum appears in 1998, N. Engl. J. Med. 339:571.] N. Engl. J. Med. 339:216.
  31. ↵
    Steere, A. C., V. K. Sikand, F. Meurice, D. L. Parenti, E. Fikrig, R. T. Schoen, J. Nowakowski, C. H. Schmid, S. Laukamp, C. Buscarino, D. S. Krause. 1998. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant: Lyme disease vaccine study group. N. Engl. J. Med. 339: 209
    OpenUrlCrossRefPubMed
  32. ↵
    Barthold, S. W., E. Fikrig, L. K. Bockenstedt, D. H. Persing. 1995. Circumvention of outer surface protein A immunity by host-adapted Borrelia burgdorferi. Infect. Immun. 63: 2255
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Zhong, W., L. Gern, T. Stehle, C. Museteanu, M. Kramer, R. Wallich, M. M. Simon. 1999. Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC. Eur. J. Immunol. 29: 946
    OpenUrlCrossRefPubMed
  34. ↵
    Zhong, W., T. Stehle, C. Museteanu, A. Siebers, L. Gern, M. Kramer, R. Wallich, M. M. Simon. 1997. Therapeutic passive vaccination against chronic Lyme disease in mice. Proc. Natl. Acad. Sci. USA 94: 12533
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Patrican, L. A.. 1997. Absence of Lyme disease spirochetes in larval progeny of naturally infected Ixodes scapularis (Acari:Ixodidae) fed on dogs. J. Med. Entomol. 34: 52
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Barthold, S. W., M. S. de Souza, J. L. Janotka, A. L. Smith, D. H. Persing. 1993. Chronic Lyme borreliosis in the laboratory mouse. Am. J. Pathol. 143: 959
    OpenUrlPubMed
  37. ↵
    Barbour, A. G.. 1984. Isolation and cultivation of Lyme disease spirochetes. Yale J. Biol. Med. 57: 521
    OpenUrlPubMed
  38. ↵
    Nazario, S., S. Das, A. M. de Silva, K. Deponte, N. Marcantonio, J. F. Anderson, D. Fish, E. Fikrig, F. S. Kantor. 1998. Prevention of Borrelia burgdorferi transmission in guinea pigs by tick immunity. Am. J. Trop. Med. Hyg. 58: 780
    OpenUrlAbstract
  39. ↵
    Reiner, S. L., S. Zheng, D. B. Corry, R. M. Locksley. 1993. Constructing polycompetitor cDNAs for quantitative PCR. J. Immunol. Methods 165: 37
    OpenUrlCrossRefPubMed
  40. ↵
    de Silva, A. M., N. S. Zeidner, Y. Zhang, M. C. Dolan, J. Piesman, E. Fikrig. 1999. Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks. Infect. Immun. 67: 30
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Stevenson, B., S. W. Barthold. 1994. Expression and sequence of outer surface protein C among North American isolates of Borrelia burgdorferi. FEMS Microbiol. Lett. 124: 367
    OpenUrlCrossRefPubMed
  42. ↵
    Moody, K. D., S. W. Barthold. 1998. Lyme borreliosis in laboratory mice. Lab. Anim. Sci. 48: 168
    OpenUrlPubMed
  43. ↵
    Sonnesyn, S. W., J. C. Manivel, R. C. Johnson, J. L. Goodman. 1993. A guinea pig model for Lyme disease. Infect. Immun. 61: 4777
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Bockenstedt, L. K., E. Hodzic, S. Feng, K. W. Bourrel, A. de Silva, R. R. Montgomery, E. Fikrig, J. D. Radolf, S. W. Barthold. 1997. Borrelia burgdorferi strain-specific Osp C-mediated immunity in mice. Infect. Immun. 65: 4661
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Immunology: 164 (10)
The Journal of Immunology
Vol. 164, Issue 10
15 May 2000
  • Table of Contents
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Arthropod- and Host-Specific Borrelia burgdorferi bbk32 Expression and the Inhibition of Spirochete Transmission
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Arthropod- and Host-Specific Borrelia burgdorferi bbk32 Expression and the Inhibition of Spirochete Transmission
Erol Fikrig, Wen Feng, Stephen W. Barthold, Sam R. Telford, Richard A. Flavell
The Journal of Immunology May 15, 2000, 164 (10) 5344-5351; DOI: 10.4049/jimmunol.164.10.5344

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Arthropod- and Host-Specific Borrelia burgdorferi bbk32 Expression and the Inhibition of Spirochete Transmission
Erol Fikrig, Wen Feng, Stephen W. Barthold, Sam R. Telford, Richard A. Flavell
The Journal of Immunology May 15, 2000, 164 (10) 5344-5351; DOI: 10.4049/jimmunol.164.10.5344
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Early Self-Regulatory Mechanisms Control the Magnitude of CD8+ T Cell Responses Against Liver Stages of Murine Malaria
  • Sublethal Hyperoxia Impairs Pulmonary Innate Immunity
  • Dependence of IL-4, IL-13, and Nematode-Induced Alterations in Murine Small Intestinal Smooth Muscle Contractility on Stat6 and Enteric Nerves
Show more HOST DEFENSE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606